A new medication for pulmonary arterial hypertension (PAH) Uptravi® (selexipag) is undergoing assessment by the Common Drug Review (CDR)
CDR reviews clinical, economic, and patient evidence, and uses this information to make recommendations to the majority of Canada’s public drug plans on whether or not medications should be funded and with what eligibility criteria. Uptravi, a prostacyclin receptor agonist, has been approved by Health Canada for the long-term treatment PAH, including those patients with scleroderma.
As part of the review process, registered patient groups such as the Pulmonary Hypertension Association of Canada (PHA) Canada and the Scleroderma Society of Canada (SSC) are invited to provide input so that patients and caregivers can be heard. Reviewers use this information as one element of their decision-making process to determine if a drug will be recommended for public reimbursement.
Your Input is Important for Current and Future Patients with PAH and Scleroderma
In order to represent the views of the people most affected by PAH, we need to hear from you. Please take a few minutes to complete our survey so that we can represent as many patients and caregivers as possible. Thank-you.